The New England Journal Of Medicine published an astonishing study and possibly record-breaking report regarding a cancer trial that reportedly become the first in the world to completely remove the disease in every patient.
The study, titled “PD-1 Blockade in Mismatch Repair—Deficient, Locally Advanced Rectal Cancer” was conducted among 12 rectal cancer patients, all of which had a “clinical complete response,” according to the authors, led by Dr. Andrea Cercek of the Memorial Sloan Kettering Cancer Center, New York City.
As originally reported by The Epoch Times, and verified by Patriot One News via the medical journal’s study, doctors have been unable to see any evidence of tumors among the patients when using magnetic resonance imaging, fludeoxyglucose F 18 injections, physical examinations, or via endoscopic evaluations, according to researchers.
Furthermore, the patients continued to show no signs of cancer during follow-ups ranging from 6 to 25 months and have not had to undergo surgery or receive radiation and chemotherapy.
Specifically, the rectal cancer patients were given dostarlimab, a monoclonal antibody, every 3 weeks for 6 months. The patients had mismatch repair-deficient stage two or three rectal adenocarcinomas, a type of cancer.
The median age of the patients enrolled was 54 years and 62 percent were women.
In the past, quite often, such cancer patients would have needed to undergo lenghty treatments like chemotherapy, radiation, or surgery and in extreme cases, be fitted with colostomy bags.
However, after taking dostarlimab, which is sold under the brand name Jemperli, no cases of progression or recurrence were reported in the patients who underwent the study.
“At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported,” according to the report.
The results of the study were also presented at the American Society of Clinical Oncology 2022 annual meeting. The authors of the study did acknowledge that extended follow-up is needed to assess the duration of response.
The study was supported by the Simon and Eve Colin Foundation, GlaxoSmithKline, Stand Up to Cancer, Swim Across America, and the National Cancer Institute of the National Institutes of Health, validating the credibility of the report.
According to Drugs.com, the cost of Jemperli intravenous solution (500 mg/10 mL) is around $11,201 for a supply of 10 milliliters. Prices are for cash-paying customers only and are not valid with insurance plans according to the website.